2026 H1 - tulosraportti
24 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 421 | - | - | ||
| 1 200 | - | - | ||
| 10 000 | - | - | ||
| 5 360 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuThe probability that Rep emi will soon be cancelled is increasing after almost 17 days without information and a longer period where the share has been traded below 4.8 kr.
·2 t sitten · MuokattuWilliam Blair has just initiated coverage of CATX with Outperform and values the stock at $11.45 against around $3 in share price. What's interesting for us is not CATX itself. It's why they are bullish, lead-212. Blair believes Pb-212 radiopharma is undervalued and that the market in the USA alone could be up to 35 billion dollars. That's exactly what TRMED is built for. Thor produces the isotopes others will use, Th-228, Ra-224 and Pb-212, and AlphaOne is underway. The more companies like CATX that get through clinical trials and the more Wall Street buys into the Pb-212 thesis, the more isotopes someone has to deliver. That's also why the price targets from the Norwegian brokerage houses vary so much. DNB has a sell rating around 4.20, while Arctic and ABG have buy ratings at 8.70 and 7. The divergence isn't about them disagreeing that Thor can produce isotopes. It's about how big they dare to project the Pb-212 wave, how quickly demand will come, and how much of that pie Thor actually takes. When a firm like William Blair starts pricing in a large American radiopharma market, it becomes clearer why some Norwegian 'champions' are cautious, and why others are already pricing in that this could become much bigger. Not a contract with CATX. But a quite clear signal that the value chain Thor is in is getting more and more attention. Not advice. Just some positive news in the early morning. It's precisely such news that lifts the industry up and forward.🫡 https://www.tradingview.com/news/benzinga:b986d5dcf094b:0-this-3-biotech-could-be-worth-11-45-analyst-says/ A little more info about William Blair. William Blair is an American investment firm, not a person in this case. It was founded in Chicago in 1935 and is still independent and partnership/employee-owned. The headquarters are in Chicago. They operate in investment banking, equity research, asset management, and private banking, with offices in a number of countries. The asset management division has approximately 70 billion dollars under management. In the CATX case, it's the equity research that counts. The analyst is named Andy Hsieh (Ph.D. in Chemistry, partner at William Blair). He has closely followed radiopharma for several years and written his own industry reports on the field. It is he who initiated coverage of Perspective Therapeutics with Outperform and a valuation estimate of $11.45. They are not Goldman Sachs or JPMorgan in size, but in biotech and midcap healthcare, they are a known name. When Blair and Hsieh get involved with a Pb-212 company, it's a signal that an established research desk takes the thesis seriously, not a random recommendation on social media. They cover CATX, not TRMED. For Thor, the point is indirect: the same desk that follows radiopharma highlights Pb-212 as an important track.
I didn't quite grasp how the repair issue was to be done. Some text about it running concurrently with the private placement. Is anything remaining? In that case, the most relevant question is probably how that process is going - in the market. If I know Brede correctly, he will com,e with an announcement about a partner or contract without a kr or figure indication along the way.- ·1 päivä sitten · MuokattuThere's a lot of TA talk in TRMED currently. I think most of it can be thrown out the window. The stock is no longer just a project on the drawing board. The factory is running, first deliveries have been made, and they have raised money for the USA. Then it's the fundamentals that govern, not old lines from the time before production. Just look at the price targets. DNB has a sell and 4,20. Arctic has a buy and 8,70. ABG has a buy and 7. When the brokerage houses diverge so much, it tells us that the uncertainty lies in the ramp-up of production, not in whether it was a rectangle at 5,98 etc. TA can still be used for timing. But building the case on formations now, I think is wrong. What matters is volume, the technology, news around the market, deliveries, and whether they are approaching profitability. The rest is mostly noise. I'm sitting here for the future. I'm not in a hurry, and I don't let my emotions control the trade. Wishing everyone a good Sunday and a good upcoming week🫡
It's been a while since a top-up, but tomorrow it's coming again for my part. And I must say it's a good feeling at this level 🫶 
·1 päivä sittenIf you had done TA four weeks ago, we would still be heading towards double digits 😬 The problem is that Thor is not in a technical phase now. The stock price is ravaged by share issues and corporate events. Drawing lines on that price and pretending the market suddenly follows the textbook becomes a bit comical…. You who are posting TA here now, do you really believe it yourselves? Nobody knows where the price is going, but statistically after such an event we are in now, the price will be pulled up rather than down. Good luck to everyone 🫢🍿
Technical analysis has proven to be thin soup in this stock, at least since I started here in October last year. But the times TA has been of the more professionally effective kind, it has been during an upturn and not a downturn. In February, the floor at 3.91 held as if it were concrete, before it reversed and went all the way to 5.72 in April. Same after April. I would rather bet on selling when it has gone up a lot, as it statistically has strong corrections. Not even Lilli Bendriss can predict Thor's next move. I believe TA is for stocks that have already established themselves and are on a stable growth basis of perhaps 20% a year. Not for stocks like Thor where we have barely started and never know the next chess move. And yes, it can give an extra little edge if one uses TA together with fundamental and macro, but then one must intertwine the three quite well. TA alone here is of little substance!
·2 päivää sitten · Muokattuguynextdoor7 I honestly think that analysis is far too contrived. You start with a bearish Elliott Wave scenario and then build a lot of levels on top, which in practice can be drawn in several different ways. When you simultaneously don't own the stock and clearly want to buy lower, it's hard not to get the impression that the analysis also very conveniently fits your own desire for a lower price. Pointing to 2.80, 2.00 and all the way down towards 1.60 solely based on wave theory seems very speculative in a small, news-driven stock like Thor. A strong announcement about sales, deliveries or production can change the whole picture in one day. So I simply don't buy the premise that the stock "must" go significantly lower before it can rise again. It's one possible technical narrative — not a definitive answer.Perhaps it depends on whether ceo gives a signal. Regarding the status of ongoing orders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
24 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuThe probability that Rep emi will soon be cancelled is increasing after almost 17 days without information and a longer period where the share has been traded below 4.8 kr.
- ·2 t sitten · MuokattuWilliam Blair has just initiated coverage of CATX with Outperform and values the stock at $11.45 against around $3 in share price. What's interesting for us is not CATX itself. It's why they are bullish, lead-212. Blair believes Pb-212 radiopharma is undervalued and that the market in the USA alone could be up to 35 billion dollars. That's exactly what TRMED is built for. Thor produces the isotopes others will use, Th-228, Ra-224 and Pb-212, and AlphaOne is underway. The more companies like CATX that get through clinical trials and the more Wall Street buys into the Pb-212 thesis, the more isotopes someone has to deliver. That's also why the price targets from the Norwegian brokerage houses vary so much. DNB has a sell rating around 4.20, while Arctic and ABG have buy ratings at 8.70 and 7. The divergence isn't about them disagreeing that Thor can produce isotopes. It's about how big they dare to project the Pb-212 wave, how quickly demand will come, and how much of that pie Thor actually takes. When a firm like William Blair starts pricing in a large American radiopharma market, it becomes clearer why some Norwegian 'champions' are cautious, and why others are already pricing in that this could become much bigger. Not a contract with CATX. But a quite clear signal that the value chain Thor is in is getting more and more attention. Not advice. Just some positive news in the early morning. It's precisely such news that lifts the industry up and forward.🫡 https://www.tradingview.com/news/benzinga:b986d5dcf094b:0-this-3-biotech-could-be-worth-11-45-analyst-says/ A little more info about William Blair. William Blair is an American investment firm, not a person in this case. It was founded in Chicago in 1935 and is still independent and partnership/employee-owned. The headquarters are in Chicago. They operate in investment banking, equity research, asset management, and private banking, with offices in a number of countries. The asset management division has approximately 70 billion dollars under management. In the CATX case, it's the equity research that counts. The analyst is named Andy Hsieh (Ph.D. in Chemistry, partner at William Blair). He has closely followed radiopharma for several years and written his own industry reports on the field. It is he who initiated coverage of Perspective Therapeutics with Outperform and a valuation estimate of $11.45. They are not Goldman Sachs or JPMorgan in size, but in biotech and midcap healthcare, they are a known name. When Blair and Hsieh get involved with a Pb-212 company, it's a signal that an established research desk takes the thesis seriously, not a random recommendation on social media. They cover CATX, not TRMED. For Thor, the point is indirect: the same desk that follows radiopharma highlights Pb-212 as an important track.I didn't quite grasp how the repair issue was to be done. Some text about it running concurrently with the private placement. Is anything remaining? In that case, the most relevant question is probably how that process is going - in the market. If I know Brede correctly, he will com,e with an announcement about a partner or contract without a kr or figure indication along the way.
- ·1 päivä sitten · MuokattuThere's a lot of TA talk in TRMED currently. I think most of it can be thrown out the window. The stock is no longer just a project on the drawing board. The factory is running, first deliveries have been made, and they have raised money for the USA. Then it's the fundamentals that govern, not old lines from the time before production. Just look at the price targets. DNB has a sell and 4,20. Arctic has a buy and 8,70. ABG has a buy and 7. When the brokerage houses diverge so much, it tells us that the uncertainty lies in the ramp-up of production, not in whether it was a rectangle at 5,98 etc. TA can still be used for timing. But building the case on formations now, I think is wrong. What matters is volume, the technology, news around the market, deliveries, and whether they are approaching profitability. The rest is mostly noise. I'm sitting here for the future. I'm not in a hurry, and I don't let my emotions control the trade. Wishing everyone a good Sunday and a good upcoming week🫡It's been a while since a top-up, but tomorrow it's coming again for my part. And I must say it's a good feeling at this level 🫶
- ·1 päivä sittenIf you had done TA four weeks ago, we would still be heading towards double digits 😬 The problem is that Thor is not in a technical phase now. The stock price is ravaged by share issues and corporate events. Drawing lines on that price and pretending the market suddenly follows the textbook becomes a bit comical…. You who are posting TA here now, do you really believe it yourselves? Nobody knows where the price is going, but statistically after such an event we are in now, the price will be pulled up rather than down. Good luck to everyone 🫢🍿Technical analysis has proven to be thin soup in this stock, at least since I started here in October last year. But the times TA has been of the more professionally effective kind, it has been during an upturn and not a downturn. In February, the floor at 3.91 held as if it were concrete, before it reversed and went all the way to 5.72 in April. Same after April. I would rather bet on selling when it has gone up a lot, as it statistically has strong corrections. Not even Lilli Bendriss can predict Thor's next move. I believe TA is for stocks that have already established themselves and are on a stable growth basis of perhaps 20% a year. Not for stocks like Thor where we have barely started and never know the next chess move. And yes, it can give an extra little edge if one uses TA together with fundamental and macro, but then one must intertwine the three quite well. TA alone here is of little substance!
- ·2 päivää sitten · Muokattuguynextdoor7 I honestly think that analysis is far too contrived. You start with a bearish Elliott Wave scenario and then build a lot of levels on top, which in practice can be drawn in several different ways. When you simultaneously don't own the stock and clearly want to buy lower, it's hard not to get the impression that the analysis also very conveniently fits your own desire for a lower price. Pointing to 2.80, 2.00 and all the way down towards 1.60 solely based on wave theory seems very speculative in a small, news-driven stock like Thor. A strong announcement about sales, deliveries or production can change the whole picture in one day. So I simply don't buy the premise that the stock "must" go significantly lower before it can rise again. It's one possible technical narrative — not a definitive answer.Perhaps it depends on whether ceo gives a signal. Regarding the status of ongoing orders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 421 | - | - | ||
| 1 200 | - | - | ||
| 10 000 | - | - | ||
| 5 360 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
24 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sitten · MuokattuThe probability that Rep emi will soon be cancelled is increasing after almost 17 days without information and a longer period where the share has been traded below 4.8 kr.
- ·2 t sitten · MuokattuWilliam Blair has just initiated coverage of CATX with Outperform and values the stock at $11.45 against around $3 in share price. What's interesting for us is not CATX itself. It's why they are bullish, lead-212. Blair believes Pb-212 radiopharma is undervalued and that the market in the USA alone could be up to 35 billion dollars. That's exactly what TRMED is built for. Thor produces the isotopes others will use, Th-228, Ra-224 and Pb-212, and AlphaOne is underway. The more companies like CATX that get through clinical trials and the more Wall Street buys into the Pb-212 thesis, the more isotopes someone has to deliver. That's also why the price targets from the Norwegian brokerage houses vary so much. DNB has a sell rating around 4.20, while Arctic and ABG have buy ratings at 8.70 and 7. The divergence isn't about them disagreeing that Thor can produce isotopes. It's about how big they dare to project the Pb-212 wave, how quickly demand will come, and how much of that pie Thor actually takes. When a firm like William Blair starts pricing in a large American radiopharma market, it becomes clearer why some Norwegian 'champions' are cautious, and why others are already pricing in that this could become much bigger. Not a contract with CATX. But a quite clear signal that the value chain Thor is in is getting more and more attention. Not advice. Just some positive news in the early morning. It's precisely such news that lifts the industry up and forward.🫡 https://www.tradingview.com/news/benzinga:b986d5dcf094b:0-this-3-biotech-could-be-worth-11-45-analyst-says/ A little more info about William Blair. William Blair is an American investment firm, not a person in this case. It was founded in Chicago in 1935 and is still independent and partnership/employee-owned. The headquarters are in Chicago. They operate in investment banking, equity research, asset management, and private banking, with offices in a number of countries. The asset management division has approximately 70 billion dollars under management. In the CATX case, it's the equity research that counts. The analyst is named Andy Hsieh (Ph.D. in Chemistry, partner at William Blair). He has closely followed radiopharma for several years and written his own industry reports on the field. It is he who initiated coverage of Perspective Therapeutics with Outperform and a valuation estimate of $11.45. They are not Goldman Sachs or JPMorgan in size, but in biotech and midcap healthcare, they are a known name. When Blair and Hsieh get involved with a Pb-212 company, it's a signal that an established research desk takes the thesis seriously, not a random recommendation on social media. They cover CATX, not TRMED. For Thor, the point is indirect: the same desk that follows radiopharma highlights Pb-212 as an important track.I didn't quite grasp how the repair issue was to be done. Some text about it running concurrently with the private placement. Is anything remaining? In that case, the most relevant question is probably how that process is going - in the market. If I know Brede correctly, he will com,e with an announcement about a partner or contract without a kr or figure indication along the way.
- ·1 päivä sitten · MuokattuThere's a lot of TA talk in TRMED currently. I think most of it can be thrown out the window. The stock is no longer just a project on the drawing board. The factory is running, first deliveries have been made, and they have raised money for the USA. Then it's the fundamentals that govern, not old lines from the time before production. Just look at the price targets. DNB has a sell and 4,20. Arctic has a buy and 8,70. ABG has a buy and 7. When the brokerage houses diverge so much, it tells us that the uncertainty lies in the ramp-up of production, not in whether it was a rectangle at 5,98 etc. TA can still be used for timing. But building the case on formations now, I think is wrong. What matters is volume, the technology, news around the market, deliveries, and whether they are approaching profitability. The rest is mostly noise. I'm sitting here for the future. I'm not in a hurry, and I don't let my emotions control the trade. Wishing everyone a good Sunday and a good upcoming week🫡It's been a while since a top-up, but tomorrow it's coming again for my part. And I must say it's a good feeling at this level 🫶
- ·1 päivä sittenIf you had done TA four weeks ago, we would still be heading towards double digits 😬 The problem is that Thor is not in a technical phase now. The stock price is ravaged by share issues and corporate events. Drawing lines on that price and pretending the market suddenly follows the textbook becomes a bit comical…. You who are posting TA here now, do you really believe it yourselves? Nobody knows where the price is going, but statistically after such an event we are in now, the price will be pulled up rather than down. Good luck to everyone 🫢🍿Technical analysis has proven to be thin soup in this stock, at least since I started here in October last year. But the times TA has been of the more professionally effective kind, it has been during an upturn and not a downturn. In February, the floor at 3.91 held as if it were concrete, before it reversed and went all the way to 5.72 in April. Same after April. I would rather bet on selling when it has gone up a lot, as it statistically has strong corrections. Not even Lilli Bendriss can predict Thor's next move. I believe TA is for stocks that have already established themselves and are on a stable growth basis of perhaps 20% a year. Not for stocks like Thor where we have barely started and never know the next chess move. And yes, it can give an extra little edge if one uses TA together with fundamental and macro, but then one must intertwine the three quite well. TA alone here is of little substance!
- ·2 päivää sitten · Muokattuguynextdoor7 I honestly think that analysis is far too contrived. You start with a bearish Elliott Wave scenario and then build a lot of levels on top, which in practice can be drawn in several different ways. When you simultaneously don't own the stock and clearly want to buy lower, it's hard not to get the impression that the analysis also very conveniently fits your own desire for a lower price. Pointing to 2.80, 2.00 and all the way down towards 1.60 solely based on wave theory seems very speculative in a small, news-driven stock like Thor. A strong announcement about sales, deliveries or production can change the whole picture in one day. So I simply don't buy the premise that the stock "must" go significantly lower before it can rise again. It's one possible technical narrative — not a definitive answer.Perhaps it depends on whether ceo gives a signal. Regarding the status of ongoing orders.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 421 | - | - | ||
| 1 200 | - | - | ||
| 10 000 | - | - | ||
| 5 360 | - | - | ||
| 250 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt